本文へスキップ

(社)東京血液疾患研究所(MRC JAPAN)は、国際MDS財団に認定されたCenter of Excellenceです。

MRC JAPANは世界最先端の
骨髄異形成症候群(MDS)の研究機関です。

論文(欧文症例報告・総説)Papers&Presentation

元に戻る

2, 欧文症例報告・総説

欧文症例報告


2011年
1 Ishii Y, Harada K, Kuroda R, Nagai H, Nakajima M, Saito N, Ogata K, Yoshida K.
Bilateral thalamic hemorrhage and intracranial injuries related to alcohol-induced thrombocytopenia. J Clin Pathol, 64, 1034-5, 2011
2007年
1 Tamura H, Okamoto M, Yamashita T, Sato C, Watanabe A, Kondo A, Tatsuguchi A, Tsuji T, Ogata K, Dan K.
Pure white cell aplasia: report of the first case associated with primary biliary cirrhosis. Int J Hematol 85, 97-100, 2007
2006年
1 Yokose N, Shioi Y, Sugisaki Y, Ohaki Y, Ogata K, Dan K.
CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-). Leuk Lymphoma 47, 1415-1417, 2006
2 Shoda T, Yoshimura M, Hayata D, Miyazawa Y, Ogata K.
Marked spherocytosis in clostridal sepsis. Int J Hematol 83, 179-180, 2006
2001年
1 Yokose N, Ogata K, Sugisaki Y, Mori S, Yamada T, An E, Dan K.
CD20-positive T cell leukemia/lymphoma: case report and review of the literature.Ann Hematol 80, 372-375, 2001
1998年
1 Luo SS, Tamura H, Yokose N, Ogata K, Dan K. F
ailure to detect anti-HTLV-1 antibody in a patient with adult T-cell leukaemia/lymphoma. Br J Haematol 103, 1207-1208, 1998
2 Tamura H, Ogata K, Mori S, An E, Tajika K, Sugisaki Y, Dan K.
Lymphoblastic lymphoma of natural killer cell origin, presenting as pancreatic tumour. Histopathology 32, 508-511, 1998
1996年
1 Tamura H, Ogata K, Yokose N, An E, Kamikubo K, Dan K, Kajii E, Nomura T.
1997年
1 Yokose N, Ogata K, Nakamura K, Kamikubo K, Tamura H, An E, Dan K, Nomura T.
Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia. Am J Hematol 55, 166-167, 1997
1995年
1 Yokose N, Ogata K, An E, Tamura H, Kamikubo K, Dan K, Nomura T.
Lineage-unrestricted hematologic response to granulocyte colony-stimulating factor in a patient with refractory anemia with excess blasts. Ann Hematol 70, 163-167, 1995
1990年
1 Ogata K, Tanabe Y, Iwakiri K, Ito T, Yamada T, Dan K, Nomura T.
Two cases of disseminated Trichosporon beigelii infection treated with combination antifungal therapy. Cancer 65, 2793-2795, 1990

欧文総説


2011年
1 Ogata K.
Flow cytometry will be a routine tool in clinical practice in myelodysplastic syndromes: a real story. Leuk Res (Editorial) 35, 848? 849, 2011
2010年
1 Valent P, Orazi A, B?sche G, Schmitt-Gr?ff A, George TI, Sotlar K, Streubel B, Beham-Schmid C, Cerny-Reiterer S, Krieger O, van de Loosdrecht A, Kern W, Ogata K, Wimazal F, Csomor J, V?rkonyi J, Sperr WR, Werner M, Kreipe H, Horny HP.
Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). Oncotarget 1, 483-96, 2010
2008年
1 Ogata K.
Diagnostic flow cytometry for low-grade myelodysplastic syndromes. Hematol Oncol 26, 193-198, 2008
2 Wells DA, Ogata K.
On flow cytometry in myelodysplastic syndromes, with caveats. Leuk Res (Editorial) 32, 209-210, 2008
2006年
1 Ogata K.
Myelodysplastic syndromes: recent progress in diagnosis and understanding of their pathophysiology. J Nippon Med Sch 73, 300-307, 2006
2005年
1 Ogata K, Yoshida Y.
Clinical implications of blast immunophenotypes in myelodysplastic syndromes.Leuk Lymphoma 46, 1269-1274, 2005
2003年
1 Tamura H, Ogata K, Dong H, Chen L.
Immunology of B7-H1 and its roles in human diseases. Int J Hematol 78, 321-328, 2003
2000年
1 Ogata K, Tamura H.
Thrombopoietin and myelodysplastic syndromes. Int J Hematol 72, 173-177, 2000
1997年
1 Yokose N, Ogata K.
Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes. Leuk Lymphoma 28, 171-176, 1997
1995年
1 Ogata K, Yokose N, Nomura T.
Interleukin-2 therapy for myelodysplastic syndrome: does it work? Leuk Lymphoma 17, 411-415, 1995
1993年
1 Ogata K, Nomura T.
Application of low-dose etoposide therapy for myelodysplastic syndromes.Leuk Lymphoma 12, 35-39, 1993



  

Supported by

Supported by

(社)東京血液疾患研究所
(MRC JAPAN)

〒182-0001
東京都調布市緑ヶ丘1-45-46
        クレナイビル3F
TEL 03-6750-1017
FAX 03-6750-1013

E-mail : info@MRCJAPAN.com